Proteostasis Therapeutics (NASDAQ:PTI) Stock Rating Upgraded by ValuEngine

Proteostasis Therapeutics (NASDAQ:PTI) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, ValuEngine reports.

Several other brokerages also recently issued reports on PTI. Zacks Investment Research downgraded Proteostasis Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 26th. Piper Jaffray Companies lowered their price target on Proteostasis Therapeutics to $5.00 and set an “overweight” rating for the company in a report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $8.75.

NASDAQ PTI traded down $0.03 during trading hours on Thursday, hitting $0.81. The company had a trading volume of 300,540 shares, compared to its average volume of 433,927. Proteostasis Therapeutics has a fifty-two week low of $0.78 and a fifty-two week high of $10.38. The stock has a market cap of $41.14 million, a P/E ratio of -0.50 and a beta of -0.66. The company has a debt-to-equity ratio of 0.13, a current ratio of 11.30 and a quick ratio of 11.29. The business’s 50 day moving average is $0.96.

Proteostasis Therapeutics (NASDAQ:PTI) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.11. The company had revenue of $5.00 million during the quarter, compared to analyst estimates of $0.80 million. As a group, equities analysts predict that Proteostasis Therapeutics will post -1.45 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in Proteostasis Therapeutics in the 4th quarter valued at about $41,000. Virtu Financial LLC bought a new position in shares of Proteostasis Therapeutics during the first quarter worth about $25,000. American International Group Inc. lifted its position in shares of Proteostasis Therapeutics by 32.9% during the fourth quarter. American International Group Inc. now owns 22,574 shares of the company’s stock worth $73,000 after purchasing an additional 5,593 shares during the last quarter. New York State Common Retirement Fund lifted its position in shares of Proteostasis Therapeutics by 6,175.0% during the fourth quarter. New York State Common Retirement Fund now owns 25,100 shares of the company’s stock worth $81,000 after purchasing an additional 24,700 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Proteostasis Therapeutics by 113.3% during the fourth quarter. Barclays PLC now owns 34,398 shares of the company’s stock worth $112,000 after purchasing an additional 18,271 shares during the last quarter. 60.11% of the stock is owned by institutional investors.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.

Featured Article: Dead Cat Bounce

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.